KYNB
Kyntra Bio, Inc. Common Stock
Nasdaq · usd
Kyntra Bio, Inc. Common Stock (KYNB) trades at $4.50 (-1.75%) as of 2:13:30 PM EDT on Oct 26, 2026, -35.88% over the past month. Market cap is $18.55M, with 3.7 days to cover in short interest.
Stock performance
How Kyntra Bio, Inc. Common Stock (KYNB) stock has performed from one day to one year, with its 52-week range.
- 1D
- -2.84%
- 1W
- -15.72%
- 1M
- -35.88%
- YTD
- -53.16%
- 1Y
- -53.16%
- 52-wk range
- $4.36 – $9.70
Key statistics
Today's trading snapshot for KYNB: day range, open, previous close, volume and market cap.
- Day range
- $4.36 – $4.65
- Open
- $4.60
- Prev close
- $4.58
- Volume
- 24.04K
- Market cap
- $18.55M
- Shares out
- 4.05M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Kyntra Bio, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- 0.10
- P/S
- 4.02
- P/B
- -0.62
- P/FCF
- —
- ROE
- -607.7%
- ROA
- 181.2%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Oct 23, 2026
8-K filings
Material corporate events Kyntra Bio, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Delisting determinationOct 6, 2026
On September 30, 2026, Kyntra Bio, Inc. received a determination letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC notifying the Company that it had not yet demonstrated compliance with Nasdaq Listing Rule 5450(b) ... and that, as a result, the Staff had determined to delist the Company's common stock from the Nasdaq Global Select Market.
- Director appointmentOct 1, 2026
Effective October 1, 2026, the Board of Directors (the "Board") of the Kyntra Bio, Inc. (the "Company" or "Kyntra Bio") appointed Andrew E. Singer, MBA as a Class III director of the Company. Mr. Singer was also appointed to the Audit Committee of the Board.
- Voluntary bankruptcyAug 31, 2026
As previously disclosed, the Company's subsidiary, FibroGen Europe, voluntarily submitted for bankruptcy to the Finnish bankruptcy court in April 2026.
- Annual meeting resultsJun 16, 2026
At the 2026 annual meeting of stockholders of Kyntra Bio, Inc. held on June 12, 2026, the stockholders voted on the three proposals listed below... The Class III director nominee, Michael Kauffman, M.D., Ph.D., was elected to hold office until the Company's 2029 annual meeting of stockholders. The director received 96.04% of the shares voting: 1,239,169 shares of Common Stock voted for, 0 against, 51,081 withheld, and 1,444,428 broker non-votes.
- Divestiture completionJun 9, 2026
On August 29, 2025, the Company closed the sale of its China operations through FibroGen International (Hong Kong) Ltd. to AstraZeneca pursuant to the Share Purchase Agreement for a total consideration of approximately $220 million comprised of $85 million in enterprise value and approximately $135 million in net cash held in China.
KYNB short interest
How heavily KYNB is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 3.7
- Short interest
- 100.04K
- Avg volume
- 26.76K
As of · reported to FINRA twice monthly.
KYNB news
The latest news and headlines about Kyntra Bio, Inc. Common Stock (KYNB).
- Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of DirectorspositiveGlobeNewswire Inc.· Oct 1, 2026
- Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial ResultsneutralGlobeNewswire Inc.· Mar 9, 2026
Frequently asked questions
What is the Kyntra Bio, Inc. Common Stock (KYNB) stock price today?
Kyntra Bio, Inc. Common Stock (KYNB) is trading at $4.50 (-1.75% on the day) as of 2:13:30 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Kyntra Bio, Inc. Common Stock?
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and…
What is the short interest in KYNB?
As of Sep 30, 2026, KYNB has 100.04K shares short and 3.7 days to cover.
What exchange is KYNB listed on?
Kyntra Bio, Inc. Common Stock (KYNB) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of KYNB with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a KYNB analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.